Skip Ribbon Commands
Skip to main content
Menu
Back To Search Results
Dr Tan Ru Yu

Dr Tan Ru Yu

MBBS, MRCP, FAMS, MMedStats

Senior Consultant

Specialty: Renal Medicine

Sub-specialties: Interventional Nephrology

Conditions Treated by this Doctor:
Acute Kidney injury, Chronic Kidney Disease, Diabetic Kidney Disease, Fluid, Electrolyte and Acid-Base Problems including Renal Tubular Acidosis and Tubulopathies, Glomerulonephritis, Haemodialysis Access Dysfunction, Hypertension, Hypertension.

Clinical Appointments

  • Senior Consultant Renal Medicine Singapore General HospitalSingapore General Hospital
  • Senior Consultant SingHealth Duke-NUS Vascular Centre

Academic Appointments

  • Clinical Assistant Professor

Profile

Dr Tan Ru Yu graduated with M.B.B.S from International Medical University of Malaysia in 2005. She obtained membership of the Royal College of Physician (United Kingdom) in 2010. She completed Advanced Specialist Training in Renal Medicine in Singapore General Hospital 2014 and was trained in dialysis access management at Westmead Hospital, Australia in 2017. She also has a Master's degree in medical statistics from University of Newcastle, Australia.

Her clinical interests include General Nephrology, Critical care and Interventional Nephrology.

Education

  • MMedStats (Australia) 2021
  • MRCP (UK) 2010
  • MBBS (Malaysia) 2005

Professional Appointments and Committee Memberships

Awards

  • Best Abstract Award 3rd Place, 4th Congress of Asian Pacific Society of Dialysis Access (2019)
  • Best Podium Abstract Award 2nd Place, Annual Scientific Meeting, American Society of Diagnostic and Interventional Nephrology (2017)
  • Best Poster Award Education Research, SingHealth Duke-NUS Scientific Meeting (2016)
  • Service with a Heart Award (2016)
  • Health Manpower Development Plan Award (2016)
  • Young Investigator Award, SGH 21st Annual Scientific Meeting (2015)

Research Interests

  • Interventional Nephrology
  • Critical Care Nephrology

Publications

  1. Tan RY, Tang TY, Tan CS. Paclitaxel-Coated Balloon Angioplasty for Dysfunctional Arteriovenous Fistulas. Am J Kidney Dis. 2022 Jan;79(1):129-130. doi: 10.1053/j.ajkd.2021.07.026. Epub 2021 Oct 12.
  2. Pang SC, Tan RY, Choke E et al. SIroliMus coated angioPlasty versus plain balloon angioplasty in the tREatment of dialySis acceSs dysfunctION (IMPRESSION): study protocol for a randomized controlled trial. Trials. 2021 Dec 20; 22(1):945. Doi:10.1186/s13063-021-05920-3
  3. Soon SXT, Tan RY, Pang SC et al. Ranger™ paclitaxel-coated balloon versus conventional balloon angioplasty for treatment of failing arteriovenous fistulas and grafts in haemodialysis patients: A retrospective study. J Vasc Access 2021 Dec 30; 11297298211067046. doi: 10.1177/11297298211067046. Online ahead of print.
  4. Tng ARK, Tan RY, Soon SXY et al. Treatment of cephalic arch stenosis in dysfunctional arteriovenous fistulas with paclitaxel-coated versus conventional balloon angioplasty. CVIR Endovasc. 2021 Nov 29;4(1):80. doi: 10.1186/s42155-021-00271-1.
  5. Tan RY, Pang SC, Tng ARK, Tan CS. Paclitaxel-coated balloon angioplasty for recurrent arteriovenous fistula stenosis. Kidney Int. 2021 Aug;100(2):480-481. doi: 10.1016/j.kint.2021.04.041.
  6. Tan HZ, Tan RY, Choo JCJ et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int. 2021 Aug;100(2):469-471. doi: 10.1016/j.kint.2021.05.009. Epub 2021 May 23.
  7. Lim CC, Tan RY, Choo JCJ et al. Estimation of risk for major bleeding in native kidney biopsies in patients with multiple risk factors. Int Urol Nephrol. 2021 Apr 29. Doi:10.1007/s11255-021-02874
  8. Tng ARK, Tan RY, Pang SC et al. Use of haemodialysis plastic cannula with ultrasound guidance in difficult arteriovenous access. Ann Acad Med Singap. 2021 Mar; 50(3):267-269
  9. Liu P, Pang SC, Tan RY et al. Outcomes of arteriovenous fistula in elderly patients on maintenance haemodialysis. Int Urol Nephrol. 2021 Mar 6. Doi:10.1007/s11255-021-02822
  10. Tan CW, Tan RY, Pang SC et al. Single-center prospective pilot study of sirolimus drug-coated balloon angioplasty in maintaining the patency of thrombosed arteriovenous graft. J Vasc Interv Radiol. 2020 Dec; 32(3):369-375
  11. Tan RY, Pang SC, Tng RKA et al. Effect of low molecular weight heparin on patency following successful salvage of arteriovenous access with recurrent thrombosis. Nephrology (Carlton). 2020; Nov 18; 26(4):350-357
  12. Zhang Z, Phang CC, Tan RY et al. Does reducing radiation levels for procedures affect image quality and radiation to proceduralist? A double blinded randomized study of two protocols. Clin Radiol, 2021; 76(2): 157.e10. doi:10.1016/j.crad.2020.09.003
  13. Tan RY, Tan CW, Pang SC et al. Study protocol of a pilot study on sirolimus-coated balloon angioplasty in salvaging clotted arteriovenous graft. CVIR Endovasc. 2020 Jul 5; 3(1): 34. doi:10.1186/s42155-020-00123-4
  14. Pang SC, Tan RY, Kwek JL et al. Current state of vascular access in Singapore. J Vasc Access. 2020 Sep;21(5): 582-588. doi:10.1177/1129729729819878595
  15. Tan RY, Pang SC, Teh SP et al. Outcomes of endovascular salvage of clotted arteriovenous access and predictors of patency after thrombectomy. J Vasc Surg 2020 Apr;71(4):1333-1339. doi: 10.1016/j.jvs2019.07.
  16. Tng ARK, Lee KG, Tan RY et al. Validation of the failure to maturation equation and proposal for a novel scoring system for arteriovenous fistula maturation in multiethnic Asian Haemodialysis patients. J Vasc Access 2020 Mar;21(2):169-175. Doi:10.1177/112979819865463 [Epub ahead of print]
  17. Phang CC, Tan RY, Pang SC et al. Paclitaxel-coated balloon in the treatment of recurrent dysfunctional arteriovenous access, a real-world experience and longitudinal follow-up. Nephrology (Carlton). 2019; 24 (12): 1290-1925. Doi: 10.1111/nep.13591
  18. Tan RY, Pang SC, Teh SP et al. Comparison of alteplase and urokinase for phamacomechnical thrombolysis of clotted hemodialysis access. J Vasc Access.2019; 20 (5):501-506. Doi:10.1177/11297298
  19. Tan RY, Chong TT, Tsai FC et al. A pilot study on adjunctive use of parametric colour-coded digital subtraction angiography in endovascular interventions of haemodialysis access. BMC Med Imaging. 2018 Sep 15;18(1):28. doi: 10.1186/s12880-018-0270-8
  20. Tan RY, Manning M, Spurway J et al. Improving haemodialysis fistula maturation following early ultrasound vascular mapping: ‘ The Venous Preservation Scan’. Nephrology (Carlton). 2019 May 20; 24(5): 550-556 doi: 10.1111/nep.13403.
  21. Tan RY, Lee KG, Gan SWS et al. Impact of simulation-based learning on immediate outcome of temporary haemodialysis catheter placements of nephrology fellows. Nephrology (Carlton). 2018 Oct; 23(10):933-939 doi: 10.1111/nep.13156.
  22. Tan RY, Allen JC Jr, Kee T et al. Predictors of low estimated glomerular filtration rate after living kidney donation in a Southeast Asian population from Singapore. Nephrology (Carlton). 2017 Oct;22(10):761-768. doi: 10.1111/nep.12845.

Research Trials

  1. Prospective, Randomized controlled trial of stEnt graft and Drug-coated bAlloon Treatment for cephalic arch stenOsis in dysfunctional arteRio-venous fistulas (PREDATOR)
  2. SIroliMus coated angioPlasty versus plain balloon angioplasty in the tREatment of dialySis acceSs dysfunctION (IMPRESSION)
  3. Sirolimus-coated bAlloon Versus pAclitaxel-coated balloon angioplasty for the treatment of dysfunctional ArterioVenous Fistula (SAVE AVF)
  4. Developing a computer aided integrated vascular scan system for automated assessment of arteriovenous (AV) access

SingHealth Updates for Healthcare Professionals

HealthXchange E-news Subscription

Health Buddy App

About Us
Patient Care
Education
Research
Careers
Giving
SingHealth
SingHealth Duke-NUS
Singapore General Hospital, Outram Road, Singapore 169608 +65 6222 3322

© 2024 SingHealth Group. All Rights Reserved.